CY1108403T1 - Κυκλικης αμινης ενωση ως ανταγωνιστης ccr5 - Google Patents
Κυκλικης αμινης ενωση ως ανταγωνιστης ccr5Info
- Publication number
- CY1108403T1 CY1108403T1 CY20081101116T CY081101116T CY1108403T1 CY 1108403 T1 CY1108403 T1 CY 1108403T1 CY 20081101116 T CY20081101116 T CY 20081101116T CY 081101116 T CY081101116 T CY 081101116T CY 1108403 T1 CY1108403 T1 CY 1108403T1
- Authority
- CY
- Cyprus
- Prior art keywords
- substituted
- group
- bond
- hydrocarbon group
- heterocyclic group
- Prior art date
Links
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 title abstract 2
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 title abstract 2
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000001434 methanylylidene group Chemical group [H]C#[*] 0.000 abstract 2
- 125000004043 oxo group Chemical group O=* 0.000 abstract 2
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 125000001931 aliphatic group Chemical group 0.000 abstract 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 230000003042 antagnostic effect Effects 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 abstract 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Μία ένωση του τύπου (Ι) (όπου το R1 είναι άτομο υδρογόνου, ομάδα υδρογονάνθρακα που μπορεί να είναι υποκατεστημένη, μία αρωματική ετεροκυκλική ομάδα η οποία μπορεί να είναι υποκατεστημένη, το R2 είναι ομάδα υδρογονάνθρακα η οποία μπορεί να είναι υποκατεστημένη, μη αρωματική ετεροκυκλική ομάδα η οποία μπορεί να είναι υποκατεστημένη ή τα R1 και R2 μπορεί να συνδυάζονται το ένα με το άλλο μαζί με το Α για να σχηματίσουν ετεροκυκλική ομάδα η οποία μπορεί να είναι υποκατεστημένη. Το Α είναι Ν ή N+-R5 *Υ-(το R5 είναι ομάδα υδρογονάνθρακα. Το Υ- είναι αντίθετο ανιόν). To R3 είναι κυκλικού υδρογονάνθρακα ομάδα η οποία μπορεί να είναι υποκατεστημένη ή ετεροκυκλική ομάδα η οποία μπορεί να είναι υποκατεστημένη. To n είναι 0 ή 1. To R4 είναι άτομο υδρογόνου, ομάδα υδρογονάνθρακα η οποία μπορεί να είναι υποκατεστημένη, ετεροκυκλική ομάδα η οποία μπορεί να είναι υποκατεστημένη, αλκόξυ ομάδα η οποία μπορεί να είναι υποκατεστημένη, αρυλόξυ ομάδα η οποία μπορεί να είναι υποκατεστημένη ή άμινο ομάδα ομάδα η οποία μπορεί να είναι υποκατεστημένη, το Ε είναι μία δισθενής αλειφατικού υδρογονάνθρακα ομάδα η οποία μπορεί να είναι υποκατεστημένη από ομάδα(ες) διαφορετικές από όξο. Το G1 είναι δεσμός , CO ή S02 To G2 είναι CO, S02, NHCO, CONH ή OCO. To J είναι μεθίνη ή άτομο αζώτου και κάθε ένα από τα Q και R είναι δεσμός ή δισθενής C1-3 αλειφατικός υδρογονάνθρακας ο οποίος μπορεί να είναι υποκατεστημένος, υπό την προϋπόθεση ότι το J είναι μεθίνη όταν το G2 είναι OCO, ότι ένα των Q και R δεν είναι δεσμός όταν το άλλο είναι δεσμός και ότι έκαστο των Q και R δεν είναι υποκατεστημένο από όξο ομάδα(ες) όταν το G1 είναι δεσμός) ή άλας αυτής έχει ισχυρή ανταγωνιστική δραστικότητα CCR5 και μπορεί προαιρετικά να χρησιμοποιηθεί για την θεραπεία ή την πρόληψη μολυσματώδους ασθένειας
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP28208899 | 1999-10-01 | ||
| JP2000046749 | 2000-02-18 | ||
| EP00962967A EP1220842B1 (en) | 1999-10-01 | 2000-09-29 | Cyclic amine compound as ccr5 antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1108403T1 true CY1108403T1 (el) | 2014-02-12 |
Family
ID=26554466
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20081101116T CY1108403T1 (el) | 1999-10-01 | 2008-10-08 | Κυκλικης αμινης ενωση ως ανταγωνιστης ccr5 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US6562978B1 (el) |
| EP (2) | EP1220842B1 (el) |
| JP (2) | JP3814136B2 (el) |
| KR (1) | KR20020060190A (el) |
| CN (1) | CN1390201A (el) |
| AR (1) | AR025884A1 (el) |
| AT (1) | ATE400555T1 (el) |
| AU (1) | AU7448700A (el) |
| BR (1) | BRPI0014428B8 (el) |
| CA (2) | CA2385938C (el) |
| CO (1) | CO5380013A1 (el) |
| CY (1) | CY1108403T1 (el) |
| DE (1) | DE60039446D1 (el) |
| DK (1) | DK1220842T3 (el) |
| ES (1) | ES2310173T3 (el) |
| HU (1) | HUP0300138A3 (el) |
| NO (1) | NO20021450L (el) |
| PE (1) | PE20010628A1 (el) |
| PL (1) | PL203984B1 (el) |
| PT (1) | PT1220842E (el) |
| WO (1) | WO2001025200A1 (el) |
| ZA (1) | ZA200202593B (el) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9903544D0 (sv) | 1999-10-01 | 1999-10-01 | Astra Pharma Prod | Novel compounds |
| GB2359078A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB2359081A (en) | 2000-02-11 | 2001-08-15 | Astrazeneca Uk Ltd | Pharmaceutically active thiazolopyrimidines |
| GB2359551A (en) | 2000-02-23 | 2001-08-29 | Astrazeneca Uk Ltd | Pharmaceutically active pyrimidine derivatives |
| GB0005642D0 (en) | 2000-03-10 | 2000-05-03 | Astrazeneca Uk Ltd | Chemical compounds |
| WO2002026714A1 (en) * | 2000-09-27 | 2002-04-04 | Takeda Chemical Industries, Ltd. | Spiro compounds |
| SE0003828D0 (sv) | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Novel compounds |
| CA2432527A1 (en) * | 2000-12-22 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Medicinal compositions for oral use |
| US6833457B1 (en) * | 2001-01-18 | 2004-12-21 | Takeda Chemical Industries, Ltd. | Process for preparation of benzylpiperidine compounds |
| SE0101322D0 (sv) | 2001-04-12 | 2001-04-12 | Astrazeneca Ab | Novel compounds |
| WO2002088089A1 (en) * | 2001-04-19 | 2002-11-07 | Banyu Pharmaceutical Co., Ltd. | Spiropiperidine derivatives, nociceptin receptor antagonists containing the same as the active ingredient and medicinal compositions |
| EP1498138A1 (en) * | 2002-04-19 | 2005-01-19 | Takeda Pharmaceutical Company Limited | Preventives for hiv infection |
| US20050245537A1 (en) * | 2002-04-24 | 2005-11-03 | Noboru Tsuchimori | Use of compounds having ccr antagonism |
| GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
| WO2004026833A1 (ja) * | 2002-09-20 | 2004-04-01 | Takeda Pharmaceutical Company Limited | 環状アミン化合物、その製造法および用途 |
| EP1553098A1 (en) * | 2002-10-18 | 2005-07-13 | Ono Pharmaceutical Co., Ltd. | Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient |
| AU2003290323A1 (en) * | 2002-12-24 | 2004-07-22 | Biofocus Plc | Compound libraries of 2h-spiro (isoquinoline-1, -piperidine derivatives and related compounds for targetting compounds capable of binding to the g-protein receptor |
| GB0328243D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Methods |
| US7498346B2 (en) | 2003-12-11 | 2009-03-03 | Genzyme Corporation | Chemokine receptor binding compounds |
| EP1708703A4 (en) | 2003-12-11 | 2008-04-09 | Anormed Inc | CHEMOKIN RECEPTOR BINDING COMPOUNDS |
| TW200630337A (en) | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| SE0403084D0 (sv) | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Chemical process |
| NZ556017A (en) * | 2004-12-24 | 2009-10-30 | Prosidion Ltd | G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes |
| US7906645B2 (en) | 2004-12-24 | 2011-03-15 | Astrazeneca Ab | Heterocyclic compounds as ccr2b antagonists |
| WO2006130426A2 (en) * | 2005-05-27 | 2006-12-07 | Kemia, Inc. | Modulators of ccr-5 activity |
| BRPI0708337A2 (pt) | 2006-02-28 | 2011-05-24 | Helicon Therapeutics Inc | pipirazinas terapêutica como inibidores pde4 |
| AU2013200480B2 (en) * | 2006-02-28 | 2016-06-09 | Dart Neuroscience (Cayman) Ltd. | Therapeutic compounds |
| NZ570847A (en) | 2006-02-28 | 2011-10-28 | Helicon Therapeutics Inc | Therapeutic compounds |
| WO2007110449A1 (en) * | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
| WO2007118854A1 (en) * | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and the use thereof |
| US8791264B2 (en) * | 2006-04-13 | 2014-07-29 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
| WO2008030853A2 (en) * | 2006-09-06 | 2008-03-13 | Incyte Corporation | Combination therapy for human immunodeficiency virus infection |
| WO2008073450A2 (en) * | 2006-12-12 | 2008-06-19 | Georgetown University | Benzamide compounds |
| GB0625523D0 (en) * | 2006-12-21 | 2007-01-31 | Ge Healthcare Ltd | In vivo imaging agents |
| WO2008124118A1 (en) * | 2007-04-09 | 2008-10-16 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use therof |
| KR101669432B1 (ko) | 2007-08-27 | 2016-10-26 | 다트 뉴로사이언스 (케이만) 엘티디. | 치료적 이속사졸 화합물 |
| WO2009040659A2 (en) * | 2007-09-28 | 2009-04-02 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| JP2010540629A (ja) | 2007-10-04 | 2010-12-24 | メルク・シャープ・エンド・ドーム・コーポレイション | カルシウムチャネル遮断薬としての置換アリールスルホン誘導体 |
| US8772297B2 (en) * | 2010-02-17 | 2014-07-08 | Kyoto University | TGF-β signal transduction inhibitor |
| AR080375A1 (es) | 2010-03-05 | 2012-04-04 | Sanofi Aventis | Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida |
| MA34215B1 (fr) | 2010-04-02 | 2013-05-02 | Phivco 1 Llc | Traitement d'association comprenant un antagoniste du récepteur ccr5, un inhibiteur de la protéase du vih-1 et un accélérateur pharmacocinétique |
| CN101921224B (zh) * | 2010-05-21 | 2012-01-18 | 中国人民解放军军事医学科学院生物工程研究所 | 1-（3-氨基丙基）哌嗪-4-氨基酰胺类化合物及其制备方法与应用 |
| KR200453948Y1 (ko) * | 2011-02-28 | 2011-06-09 | 최문희 | 파마로드 |
| WO2013024022A1 (en) | 2011-08-12 | 2013-02-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for treatment of pulmonary hypertension |
| CN103130709B (zh) * | 2011-11-22 | 2017-04-12 | 常州亚邦制药有限公司 | 具有抗hiv活性的3‑氨基丙酸哌啶酰胺类化合物，合成方法及用途 |
| BR112014015197A8 (pt) | 2011-12-21 | 2017-06-13 | Novira Therapeutics Inc | agentes antivirais de hepatite b |
| KR102271574B1 (ko) | 2012-08-28 | 2021-07-01 | 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 | 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도 |
| WO2014131847A1 (en) | 2013-02-28 | 2014-09-04 | Janssen R&D Ireland | Sulfamoyl-arylamides and the use thereof as medicaments for the treatment of hepatitis b |
| MX353412B (es) | 2013-04-03 | 2018-01-10 | Janssen Sciences Ireland Uc | Derivados de n-fenil-carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b. |
| DK2997019T3 (en) | 2013-05-17 | 2018-12-03 | Janssen Sciences Ireland Uc | SULFAMOYLTHIOPHENAMIDE DERIVATIVES AND USE THEREOF AS MEDICINES FOR TREATING HEPATITIS B |
| TWI733288B (zh) | 2013-05-17 | 2021-07-11 | 愛爾蘭商健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療ｂ型肝炎藥物的用途 |
| HRP20180791T1 (hr) | 2013-07-25 | 2018-09-07 | Janssen Sciences Ireland Uc | Glioksamid supstituirani derivati pirolamida i njihova uporaba kao lijekova za liječenje hepatitisa b |
| CA2923712C (en) * | 2013-10-23 | 2021-11-02 | Janssen Sciences Ireland Uc | Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
| US10392349B2 (en) | 2014-01-16 | 2019-08-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
| CA2936947A1 (en) | 2014-02-05 | 2015-08-13 | Novira Therapeutics, Inc. | Combination therapy for treatment of hbv infections |
| TW201620893A (zh) | 2014-02-06 | 2016-06-16 | 健生科學愛爾蘭無限公司 | 磺醯胺基吡咯醯胺衍生物及其用作治療ｂ型肝炎之醫藥品的用途 |
| US10752588B2 (en) | 2014-12-19 | 2020-08-25 | The Broad Institute, Inc. | Dopamine D2 receptor ligands |
| WO2016100940A1 (en) | 2014-12-19 | 2016-06-23 | The Broad Institute, Inc. | Dopamine d2 receptor ligands |
| US10875876B2 (en) | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| AU2017248828A1 (en) | 2016-04-15 | 2018-11-01 | Janssen Sciences Ireland Uc | Combinations and methods comprising a capsid assembly inhibitor |
| IL283725B2 (en) | 2017-06-20 | 2024-04-01 | Imbria Pharmaceuticals Inc | Compositions and methods for increasing efficiency of cardiac metabolism |
| MX2020009531A (es) | 2018-03-14 | 2020-10-05 | Janssen Sciences Ireland Unlimited Co | Regimen posologico del modulador del ensamblaje de la capside. |
| WO2020028482A1 (en) * | 2018-07-31 | 2020-02-06 | The Trustees Of The University Of Pennsylvania | Small molecules that sensitize hiv-1 infected cells to antibody dependent cellular cytotoxicity |
| EP3866794B1 (en) | 2018-10-17 | 2024-12-04 | Imbria Pharmaceuticals, Inc. | Methods of treating rheumatic diseases using trimetazidine-based compounds |
| WO2020169784A1 (en) | 2019-02-22 | 2020-08-27 | Janssen Sciences Ireland Unlimited Company | Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases |
| AR119732A1 (es) | 2019-05-06 | 2022-01-05 | Janssen Sciences Ireland Unlimited Co | Derivados de amida útiles en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb |
| EP3976101A4 (en) | 2019-05-31 | 2023-06-21 | Imbria Pharmaceuticals, Inc. | FIBROSIS TREATMENT METHODS USING COMPOUNDS THAT PROMOTE GLUCOSE OXIDATION |
| US11629196B2 (en) | 2020-04-27 | 2023-04-18 | Incelldx, Inc. | Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions |
| US11780811B2 (en) | 2020-06-30 | 2023-10-10 | Imbria Pharmaceuticals, Inc. | Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| US11530184B2 (en) | 2020-06-30 | 2022-12-20 | Imbria Pharmaceuticals, Inc. | Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate |
| CN114478585A (zh) * | 2020-10-26 | 2022-05-13 | 上海青煜医药科技有限公司 | 含氮稠杂环类化合物及其制备方法和应用 |
| WO2022223007A1 (zh) * | 2021-04-23 | 2022-10-27 | 中国人民解放军军事科学院军事医学研究院 | 抗病毒多肽化合物 |
| US11883396B2 (en) | 2021-05-03 | 2024-01-30 | Imbria Pharmaceuticals, Inc. | Methods of treating kidney conditions using modified forms of trimetazidine |
| WO2023107547A2 (en) * | 2021-12-08 | 2023-06-15 | Kineta, Inc. | Azetidine and spiroazetidine compounds and uses thereof |
| AU2023296161A1 (en) * | 2022-06-13 | 2025-01-02 | Alivexis, Inc. | Azacycloalkyl carbonyl cyclic amine compound |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4203988A (en) | 1975-11-12 | 1980-05-20 | Merck & Co., Inc. | Pyridinyl ureas and pharmaceutical use |
| JPH0680054B2 (ja) * | 1985-06-19 | 1994-10-12 | 吉富製薬株式会社 | ピペリジン誘導体 |
| EP0693070B1 (en) * | 1993-04-05 | 2002-07-24 | Pharmaceutical Discovery Corporation | PYRIDO[2,3-b](1,4)BENZODIAZEPINONES AS M2 RECEPTOR LIGAND FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| CA2296314A1 (en) | 1997-07-25 | 1999-02-04 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| AR013669A1 (es) * | 1997-10-07 | 2001-01-10 | Smithkline Beecham Corp | Compuestos y metodos |
| JP2002501898A (ja) | 1998-02-02 | 2002-01-22 | メルク エンド カムパニー インコーポレーテッド | ケモカイン受容体活性の環状アミン調節剤 |
| US6833457B1 (en) * | 2001-01-18 | 2004-12-21 | Takeda Chemical Industries, Ltd. | Process for preparation of benzylpiperidine compounds |
-
2000
- 2000-09-28 AR ARP000105104A patent/AR025884A1/es not_active Application Discontinuation
- 2000-09-28 PE PE2000001025A patent/PE20010628A1/es not_active Application Discontinuation
- 2000-09-29 CN CN00815683A patent/CN1390201A/zh active Pending
- 2000-09-29 AT AT00962967T patent/ATE400555T1/de active
- 2000-09-29 HU HU0300138A patent/HUP0300138A3/hu unknown
- 2000-09-29 CA CA2385938A patent/CA2385938C/en not_active Expired - Lifetime
- 2000-09-29 AU AU74487/00A patent/AU7448700A/en not_active Abandoned
- 2000-09-29 KR KR1020027004238A patent/KR20020060190A/ko not_active Abandoned
- 2000-09-29 DK DK00962967T patent/DK1220842T3/da active
- 2000-09-29 US US10/089,374 patent/US6562978B1/en not_active Expired - Lifetime
- 2000-09-29 PT PT00962967T patent/PT1220842E/pt unknown
- 2000-09-29 BR BRPI0014428A patent/BRPI0014428B8/pt not_active IP Right Cessation
- 2000-09-29 JP JP2000302841A patent/JP3814136B2/ja not_active Expired - Lifetime
- 2000-09-29 ES ES00962967T patent/ES2310173T3/es not_active Expired - Lifetime
- 2000-09-29 EP EP00962967A patent/EP1220842B1/en not_active Expired - Lifetime
- 2000-09-29 PL PL356034A patent/PL203984B1/pl unknown
- 2000-09-29 DE DE60039446T patent/DE60039446D1/de not_active Expired - Lifetime
- 2000-09-29 CO CO00074305A patent/CO5380013A1/es not_active Application Discontinuation
- 2000-09-29 EP EP07119933A patent/EP1886994A1/en not_active Withdrawn
- 2000-09-29 CA CA002608807A patent/CA2608807A1/en not_active Abandoned
- 2000-09-29 WO PCT/JP2000/006755 patent/WO2001025200A1/en not_active Ceased
-
2002
- 2002-03-22 NO NO20021450A patent/NO20021450L/no not_active Application Discontinuation
- 2002-04-03 ZA ZA200202593A patent/ZA200202593B/en unknown
- 2002-06-20 JP JP2002180545A patent/JP2003048880A/ja not_active Withdrawn
- 2002-10-18 US US10/273,111 patent/US7348324B2/en not_active Expired - Lifetime
-
2008
- 2008-10-08 CY CY20081101116T patent/CY1108403T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1108403T1 (el) | Κυκλικης αμινης ενωση ως ανταγωνιστης ccr5 | |
| DE69833036D1 (de) | Sulfonylderivate | |
| DK1260512T3 (da) | Hidtil ukendte, cykliske amidderivater | |
| DE69827785D1 (de) | 1,4-substituierte cyclische aminderivate | |
| CY1107532T1 (el) | Παραγωγα ναφθυριδινης, παρασκευη και χρηση τους ως αναστολεις του ισοενζυμου 4 της φωσφοδιεστepασης (pde4) | |
| DK1140916T3 (da) | Heteroaryl-cykliske acetaler | |
| CY1114240T1 (el) | Παραγωγα σουλφοναμιδιου τετραϋδροϊσοκινολινης, η παρασκευη τους και η χρηση τους στη θεραπευτικη | |
| HUP0102930A2 (hu) | Vírusellenes makrociklusos vegyületek, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
| HUP0100064A2 (hu) | Amidszármazékot és klórtalonilt tartalmazó, szinergetikus fungicid kombináció és alkalmazása | |
| EP0798292A4 (en) | ANILINE DERIVATIVES AS NITROGEN MONOXIDE SYNTHASE INHIBITORS | |
| CY1107206T1 (el) | Παραγωγα οξαζολιου/θειαζολιου ενεργοποιητες του υποδοχεα hppar-a | |
| ATE132868T1 (de) | Azabicyclo- und azacyclooxime und -amine mit cholinergischer wirkung und ihre pharmazeutisch annehmbaren salze | |
| ATE132139T1 (de) | Diaminoethylen-verbindungen | |
| WO2005011697A3 (en) | Sulfonamide derivatives with activity on protein kinase a and b | |
| EP1375496A4 (en) | N-ARYL SUBSTITUTED CYCLIC AMINE DERIVATIVE AND MEDICAMENT CONTAINING SAID DERIVATIVE AS ACTIVE INGREDIENT | |
| HRP20070286T3 (en) | Substituted diketopiperazines and their use as oxytocyn antagonists | |
| DE69319939D1 (de) | Aminobenzoesäure Derivate | |
| NO20053997D0 (no) | Oligosaccharidderivat | |
| ATE513888T1 (de) | Aromatische verbindungen mit kondensierten ringen,materialien für lichtemittierende geräte und lichtemittierende geräte in denen solche verwendet werden | |
| NO179835C (no) | Aminderivater med fungicid aktivitet og anvendelse som fungicider | |
| TH85134A (th) | อนุพันธ์ไอโซอินโดลีนต่าง ๆ | |
| ECSP003624A (es) | Nuevos compuestos espiro |